View of Cost-effectiveness analysis of the subcutaneous use of Lanadelumab for prevention of recurrent attacks of hereditary angioedema in the healthcare of the Republic of Kazakhstan

Return to Article Details Cost-effectiveness analysis of the subcutaneous use of Lanadelumab for prevention of recurrent attacks of hereditary angioedema in the healthcare of the Republic of Kazakhstan Download Download PDF